NCCN Guidelines recommend lorlatinib for second-line ROS1+ NSCLC

The new National Comprehensive Cancer Network (NCCN) Guidelines for non-small cell lung cancer (NSCLC) added lorlatinib as a ROS1 treatment option, after progression on crizotinib or ceritinib. This means most insurance should start covering lorlatinib for ROS1.

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer (Version 2.2019)
(subscription required, but it’s free)

  • Subsequent Therapy for ROS1 Rearrangement-Positive Metastatic NSCLC
    (NSCL-24)

    • Lorlatinib (category 2A) added as a treatment option, after progression on crizotinib or ceritinib.

2 thoughts on “NCCN Guidelines recommend lorlatinib for second-line ROS1+ NSCLC”

  1. Hi
    Why would Pfizer South Africa register Xalkori for ALK+ and not for Ros1+
    Regards
    Ruth

    1. It’s a battle to get a targeted therapy approved for the first time in any country. Pfizer has Phase 3 crizotinib trial data for ALK NSCLC, which has proven essential in getting the drug approved in many countries with national health systems. Because ROS1 is a small population, no phase 3 data for crizotinib exists, so it’s more difficult to get crizotinib approved for ROS1 (It’s still not approved in Canada or Australia, despite years of trying).

Comments are closed.